Clinical Research Directory
Browse clinical research sites, groups, and studies.
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Sponsor: Dana-Farber Cancer Institute
Summary
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought that IL-2 may help control chronic GVHD by stopping the donor's immune system from 'rejecting' your body. In this research study, we are looking to see how IL-2 can be used in combination with steroids to treat cGVHD.
Official title: A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2011-07
Completion Date
2026-12
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
Interleukin-2
Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
Locations (3)
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States